Streamex Acquires 9.9% Stake in Empress Royalty for Over $12 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: Newsfilter
- Strategic Investment: Streamex acquired 12,671,297 shares of Empress Royalty for $12,218,751 through a share purchase agreement with Terra Capital, establishing strong demand for STEX stock at a premium price of $5.00 per share.
- Market Premium: The transaction was executed at a premium to the market price, reflecting increased investor confidence following Streamex's previous equity financing at $3.90 per share in August 2025.
- Asset Diversification: Empress Royalty focuses on gold and silver royalties and streaming assets, aligning with Streamex's long-term strategy to enhance exposure to real yield-generating assets, thereby expanding its influence in the commodities market.
- Integration of Digital Infrastructure: This investment supports Streamex's mission to integrate royalties with modern, regulated on-chain digital infrastructure, accelerating the adoption of real-world asset tokenization across global markets and positioning the company at the forefront of fintech innovation.
Analyst Views on STEX
Wall Street analysts forecast STEX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STEX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.120
Low
12.00
Averages
12.00
High
12.00
Current: 3.120
Low
12.00
Averages
12.00
High
12.00
About STEX
Streamex Corp., formerly BioSig Technologies, Inc., is a real world asset (RWA) tokenization company. The Company with institutional grade infrastructure brings the gold and commodities market on chain, enabled by a gold denominated treasury and tokenization technology powering the modern commodities market. The Company is a wholly owned subsidiary of BioSig Technologies, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
